Results 21 to 30 of about 295,979 (212)

Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus

Arthritis Research & Therapy, 2018
Background The application of more sensitive imaging techniques, such as ultrasonography (US), changed the concept of non-erosive arthritis in systemic lupus erythematosus (SLE), underlining the need for biomarkers to identify patients developing the ...
Fulvia Ceccarelli, Carlo Perricone, Tania Colasanti, Laura Massaro, Enrica Cipriano, Monica Pendolino, Francesco Natalucci, Riccardo Mancini, Francesca Romana Spinelli, Guido Valesini, Fabrizio Conti, Cristiano Alessandri   +11 more
doaj   +1 more source

Hydroxychloroquine availability during COVID-19 crisis and its effect on patient anxiety

Lupus Science and Medicine, 2021
Objective To report the results of a survey exploring the experience of patients with SLE facing hydroxychloroquine (HCQ) shortage that occurred during the early phases of the COVID-19 pandemic.Methods A survey was designed by Lupus Europe’s patient ...
Alain Cornet, Chiara Tani, Marta Mosca, Jeanette Andersen   +3 more
doaj   +1 more source

Lack of the long pentraxin PTX3 promotes autoimmune lung disease but not glomerulonephritis in murine systemic lupus erythematosus. [PDF]

, 2011
The long pentraxin PTX3 has multiple roles in innate immunity. For example, PTX3 regulates C1q binding to pathogens and dead cells and regulates their uptake by phagocytes. It also inhibits P-selectin-mediated recruitment of leukocytes.
Mantovani Alberto, Heni Eka Susanti, Adriana Migliorini, A. Migliorini, Susanti, Heni Eka, Hans-Joachim Anders, Christoph Römmele, Kulkarni, Onkar P., M. Lech, Cecilia Garlanda, Kulkarni Onkar P., Lech, Maciej, Lech Maciej, Garlanda Cecilia, C. Garlanda, Römmele, Christoph, Migliorini Adriana, Mantovani, Alberto, Alberto Mantovani, Anders Hans-Joachim, Onkar P Kulkarni, Maciej Lech, Susanti Heni Eka, A. Mantovani, Anders, Hans-Joachim, Römmele Christoph, H.E. Susanti, Migliorini, Adriana, O.P. Kulkarni, C. Römmele, H. J. Anders, Garlanda, Cecilia, Onkar P. Kulkarni   +32 more
core   +1 more source

Joint involvement in patients affected by systemic lupus erythematosus: application of the swollen to tender joint count ratio

Reumatismo, 2015
Joint involvement is a common manifestation in systemic lupus erythematosus (SLE). According to the SLE disease activity index 2000 (SLEDAI-2K), joint involvement is present in case of ≥2 joints with pain and signs of inflammation.
E. Cipriano, F. Ceccarelli, L. Massaro, F. R. Spinelli, C. Alessandri, C. Perricone, G. Valesini, F. Conti   +7 more
doaj   +1 more source

Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus

ACR Open Rheumatology, 2021
Objectives Patients with systemic lupus erythematosus (SLE) are usually treated with glucocorticosteroids even during periods of clinically quiescent disease.
Konstantinos Tselios, Dafna D. Gladman, Jiandong Su, Murray B. Urowitz   +3 more
doaj   +1 more source

Lupus nephritis and lupus band test [PDF]

Postgraduate Medical Journal, 1981
Summary Twenty-seven patients with histologically confirmed lupus nephritis were studied to identify the incidence of lupus band and its significance to histological patterns of nephritis and complement levels. It was found that the kidney involvement is 2.5 times more frequent in lupus band positive patients.
B A, Adam, F, Wang, L M, Looi, K, Prathap   +3 more
openaire   +2 more sources

Serum anti-lipocalin 2 IgG is a novel biomarker in the diagnosis of systemic lupus erythematosus [PDF]

, 2014
Background: Previous work suggests that lipocalin 2 is involved in the pathogenesis of systemic lupus erythematosus (SLE) and that this novel antigen could serve as a high-quality renal biomarker of acute kidney injury in SLE.
Du, Y, Li, R., Li, Z. G., Ascherman, D P, Li, Y N, Feng, M, Hu, F L, Dai, Y J, Li, Z G, Jia, Y., Li, Y. N., Feng, M., Zhu, L, Zhu, L., Ma, X X, Du, Y., Ascherman, D. P., Jia, Y, Zhang, C. F., Ma, X. X., Dai, Y. J., Hu, F. L., Li, R, Zhang, C F   +23 more
core   +1 more source

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol

Trials, 2023
Background Sequential B cell-targeted immunotherapy with BAFF antagonism (belimumab) and B cell depletion (rituximab) may enhance B cell targeting in ANCA-associated vasculitis (AAV) through several mechanisms.
Mark E. McClure, Seerapani Gopaluni, James Wason, Robert B. Henderson, Andre Van Maurik, Caroline C.O. Savage, Charles D. Pusey, Alan D. Salama, Paul A. Lyons, Jacinta Lee, Kim Mynard, David R. Jayne, Rachel B. Jones, on behalf the COMBIVAS investigators   +13 more
doaj   +1 more source

The serum levels of connective tissue growth factor in patients with systemic lupus erythematosus and lupus nephritis [PDF]

, 2014
Objective: The expression of connective tissue growth factor mRNA in human kidneys may serve as an early marker for lupus nephritis progression. Therefore, we speculated that connective tissue growth factor may be involved in the pathogenesis of systemic
Wang, F-M, Zhao, M-H, Liu, G., Yu, F., Tan, Y.   +4 more
core   +1 more source

Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus [PDF]

, 2020
Objective Persistent positivity for lupus anticoagulant has been associated with an increased risk of thrombosis among patients with SLE. Persistent positivity is often defined as having two positive assessments separated by more than 90 days.
Avci, Mertcan, Magder, Laurence S., Petri, Michelle A.   +2 more
core   +1 more source